DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gianni L, Huang C-S, Egle D. et al.
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study.
San Antonio Breast Cancer Symposium 2019;
2019: GS3-04
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.